Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183677 · ClinicalTrials.gov registry record · Phase 4
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
A Phase 4 study of Depression, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT00183677: Completed Phase 4 study of Depression, sponsored by Massachusetts General Hospital.
NCT00183677 is a Phase 4 study of Depression that has completed, run by Massachusetts General Hospital. The registered enrollment target is 97 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00183677, a Phase 4 study of Depression, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.
Conditions Studied
Interventions
- DRUG Escitalopram
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2003-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183677
The ClinicalTrials.gov registry entry for NCT00183677 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Escitalopram is the first listed.
NCT00183677 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00183677 about?
NCT00183677 is a clinical study titled "Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram". This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.
What is the current status of trial NCT00183677?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 97 participants. The study started on 2003-07. Estimated completion is 2009-06.
What conditions does trial NCT00183677 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00183677?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00183677?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00183677 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.